Sat, Oct 25, 2014, 8:46 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • williams4076 williams4076 Nov 10, 2012 2:38 PM Flag

    The February challenge to BP

    You'll either pay big now or pay more with competition come Anchor indication & sNDA before the end of February.

    Currently there are no PPS estimates that fully include Anchor indication.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • father_mari Nov 11, 2012 12:11 PM Flag

      It is true, Williams actually does not even know what AMR 101 is.

      He's an absolute #$%$

      Spending so much time on Amarin's message board pushing the stock when he didn't even know what they hope to sell.

      Here are some comments that I saw just skimming through his posts.

      Can you believe how ignorant this numbskull is?


      • williams4076 Re: CAN I BUY - EPA with NO DHA today? 4-Jul-12 06:29 pm

      Plus EPA is made from the fish in the sea, correct?

      AMR101 is chemically engineered by a pharmaceutical company.

      With the Anchor and Marine indication, Plus EPA wouldn't pass the purity or supply demand for the REAL pharmaceutical grade AMR 101.

      • williams4076 Re: Question 2-Jul-12 10:18 pm

      It's produced in a lab not fished out of the sea. No drug developed from fish or krill products will be able to meet AMR 101 indication.

      • williams4076 Re: What would buyout offer be? 2-Jul-12 11:03 am

      Honestly, anything that has to be caught in a net will not fill the market need.

      What's the chemical entity that producing the results? EPA? Unknown?

      I sure hope this dummy keeps on offering his opinion on this board. I agree that his is a real dipsh*t.

      Sentiment: Hold

    • Cazook

      Don't downplay your insight! Amarin should take nothing less than the Anchor, Even REDUCE-IT's possible... In BO! Hang tuff most of the shares traded are HF to same HF act. Only a newbe would not recognize the real potential.

    • Listen! |You are selling the drug as a whole. Marine AND ANCHOR. You are saying that if the company is sold you are just selling for the marine indication? You really think that Joe is going to sell just for the marine indication? LOL|! Why do people believe that the target price these analyst come with would be the buyout price?

    • Okay thanks wiliam. Too bad none of your predictions have ever come to fruition!

      Still waiting for the $50 buyout LOL

    • Hi Williams
      Re " currently no PPS estimates that include Anchor "
      Why would you want to sell the company until Anchor is fully included in the price ?
      Just wondering ?

      Sentiment: Buy

      • 2 Replies to akanz2
      • Hi Akanz

        Great question! That's the point I'm trying to make. Amarin shouldn't take anything but a full offer that includes the Anchor indication. I didn't invest in Amarin because I thought the Marine indication would be a blockbuster. I'm here for Anchor, REDUCE-IT, and off label depression, ADHD, Autism, Irritable Bowel, Arthritis...the indications that will make Vascepa the most profitable prescription drug of all time.

        Amarin put the heat on BP to pay for the Anchor indication upfront by disclosing the February timeline and not taking the Anchor indation to market alone. IMO an absolutely brilliant negotiating move.

        I would like to see some professional articles on NCE and full Anchor indication sales projections and PPS estimates. This is the price Amarin's looking for now, IMO.

        Sentiment: Strong Buy

      • Sorry ...mean't BEFORE Anchor indication is included in the price

        Sentiment: Buy

0.94-0.11(-10.48%)Oct 24 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.